Simone D'Adamio Marina Talamonti Luca Bianchi Marco Galluzzo


Cutaneous reactions attributable to chemotherapy too often result in a modification of patients treatment plan. Most treatments remain largely unproven: only small series or case reports may indicate possible treatment options. Main observations: We reported the case of a male patient with gemcitabine-induced skin reaction occurred after a cycle of therapy with carboplatin plus gemcitabine following a 21 days schedule. The patient came to our attention for an extensive, well-demarked, erythematous, lilaceous, warm indurated lesion, covering his dorsal faces of both hands, without systemic symptoms. Clobetasol propionate 0.05% ointment was prescribed as main therapy, followed by a cream containing boswellic acids. Conclusions: It is presumable that similar dermatological lesions consist in a ‘radiation recall reaction whereby an inflammatory reaction occurs in the area previously treated with radiotherapy or affected by a sun-burn in the past. In our patient, interestingly, there is no history of radiotherapy even if there is history of strong sun exposure. Pharmacological anti-inflammatory effect due to boswellic acids was studied and relieved only in radiation-induced dermatitis, and even if larger studies would have been set in order to have more effective results, it would be useful to study application of this compound in chemotherapy-induced cutaneous adverse reactions too.



gemcitabine, chemotherapy-related skin toxicity, photo-recall skin reaction, boswelic acids

1. Sanborn RE, Sauer DA. Cutaneous reactions to chemotherapy: commonly seen, less described, little understood. Dermatol Clin 2008; 26:103-119.
2. Wyatt AJ, Leonard GD, Sachs DL. Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol 2006; 7(1):45-63.
3. Sederholm C, Hillerdal G, Lamberg K. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 2005; 23(33):8380-8388.
4. Yuh YJ, Lee HR, Kim SR. Gemcitabine and carboplatin combination chemotherapy for elderly patients with advanced non-small cell lung cancer: a feasibility study. Cancer Res Treat 2008; 40(3):116-120.
5. Kuku I, Kaya E, Sevinc A, et al. Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma J Eur Acad Dermatol Venereol 2002; 16:271-272.
6. Tan DH, Bunce PE, Liles WC, et al. Gemcitabine-related “pseudocellulitis”: report of 2 cases and review of the literature. Clin Infect Dis 2007; 45:e72–76.
7. Togni S, Maramaldi G, Bonetta A, et al. Clinical evaluation of safety and efficacy of Boswellia -based cream for prevention of adjuvant radiotherapy skin damage in mammary carcinoma: a randomized placebo controlled trial. Eur Rev Med Pharmacol Sci 2015; 19(8):1338-1344.
8. Brandes A, Reichmann U, Plasswilm L, et al. Time- and dose-limiting erysipeloid rash confined to areas of lymphedema following treatment with gemcitabine - a report of three cases. Anticancer Drugs 2000; 11(1):15-17.
9. Korniyenko A, Lozada J, Ranade A, et al. Recurrent lower extremity pseudocellulitis. Am J Ther 2012; 19(4):e141-142.
10. Zustovich F, Pavei P, Cartei G. Erysipeloid skin toxicity induced by gemcitabine. J Eur Acad Dermatol Venereol 2006; 20(6):757-758.
11. Ruiz-Casado A, Gutiérrez D, Juez I. Erysipeloid rash: A rare adverse event induced by gemcitabine. J Cancer Res Ther 2015; 11(4):1024.
12. Tan E: Skin toxicity of chemotherapy drugs [ available at 12.26.2017].
How to Cite
D'Adamio, S., Talamonti, M., Bianchi, L., & Galluzzo, M. (2017). Photo-recall cutaneous reaction to gemcitabine. Archive of Clinical Cases, 4(4), Arch Clin Cases 2017; 4(4):191-194.
Case Reports

How to Cite

D'Adamio, S., Talamonti, M., Bianchi, L., & Galluzzo, M. (2017). Photo-recall cutaneous reaction to gemcitabine. Archive of Clinical Cases, 4(4), Arch Clin Cases 2017; 4(4):191-194.